DENIM Clinical Study

The official title of the DENIM clinical study is: Dendritic Cell-based immunotherapy to treat Malignant Mesothelioma (H2020MM04).

In the DENIM clinical trial, standard chemotherapy is followed by either Best Supportive Care or dendritic cell immunotherapy called MesoPher®. These two treatment options will be compared.

Inclusion for the DENIM study will start in the second half of 2017.

Prof. Joachim Aerts MD PhD, pulmonary oncologist at Erasmus MC is coordinator of the DENIM study.

H2020MM04: A European Effort

The DENIM clinical study is a collaboration between six leading European university hospitals, the European Cancer Patient Coalition and Amphera BV, a Dutch biotech company.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668769
Read about the consortium and researchers